COHANCE

✅ Business & Corporate Profile

Cohance Lifesciences is an Indian CDMO (Contract Development & Manufacturing Organisation) and API (Active Pharmaceutical Ingredient) company headquartered in Hyderabad. It has a manufacturing footprint across multiple sites in Andhra Pradesh (e.g., Jaggayapet, Anakapalli) with plants capable of handling advanced chemistries (hydrogenation, cyanidation, Grignard, etc) and regulatory accreditations (USFDA, WHO-GMP, EDQM). The company was formerly the API/CDMO platform aggregated by the private-equity firm Advent International, via acquisitions of entities such as RA Chem Pharma, ZCL Chemicals, Avra Laboratories and others. A key recent development: the earlier company Suven Pharmaceuticals Ltd has changed its name to Cohance Lifesciences (effective 7 May 2025) following a Scheme of Amalgamation. The business is positioned to target high-end API/ specialty chemical manufacturing, CDMO services for global pharma players, and integrated manufacturing capabilities. 📊 Key Metrics & Highlights Market Cap: In the region of ₹ 34,000 crore (as of recent data) under the ticker “COHANCE”. Valuation: High P/E and high P/B in recent data, indicating strong investor valuation expectations. Operations: Multiple manufacturing units — for example: API Unit I in Jaggayapet with 522 KL reactor capacity, 117 reactors of various types; API Unit II in Atchutapuram with 142 KL capacity. Strategic focus: Scale-up of CDMO/API platform, combining chemistries, global regulatory approvals, and supply-chain diversification (away from reliance on China). 🎯 Strengths & Strategic Positives Manufacturing footprint & capabilities: The array of plants with high end chemistry capability is a strong asset in the Indian CDMO/API space.